163 related articles for article (PubMed ID: 31359391)
41. Retinoid X Receptor Selective Agonists and their Synthetic Methods.
Wagner CE; Jurutka PW; Marshall PA; Heck MC
Curr Top Med Chem; 2017; 17(6):742-767. PubMed ID: 27320333
[TBL] [Abstract][Full Text] [Related]
42. Retinoid and thiazolidinedione therapies in melanoma: an analysis of differential response based on nuclear hormone receptor expression.
Klopper JP; Sharma V; Berenz A; Hays WR; Loi M; Pugazhenthi U; Said S; Haugen BR
Mol Cancer; 2009 Mar; 8():16. PubMed ID: 19267912
[TBL] [Abstract][Full Text] [Related]
43. The rexinoid LG100754 is a novel RXR:PPARgamma agonist and decreases glucose levels in vivo.
Cesario RM; Klausing K; Razzaghi H; Crombie D; Rungta D; Heyman RA; Lala DS
Mol Endocrinol; 2001 Aug; 15(8):1360-9. PubMed ID: 11463859
[TBL] [Abstract][Full Text] [Related]
44. Modeling, synthesis and biological evaluation of potential retinoid X receptor-selective agonists: novel halogenated analogues of 4-[1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)ethynyl]benzoic acid (bexarotene).
Furmick JK; Kaneko I; Walsh AN; Yang J; Bhogal JS; Gray GM; Baso JC; Browder DO; Prentice JL; Montano LA; Huynh CC; Marcus LM; Tsosie DG; Kwon JS; Quezada A; Reyes NM; Lemming B; Saini P; van der Vaart A; Groy TL; Marshall PA; Jurutka PW; Wagner CE
ChemMedChem; 2012 Sep; 7(9):1551-66. PubMed ID: 22927238
[TBL] [Abstract][Full Text] [Related]
45. Regulation of retinoid-induced differentiation in embryonal carcinoma PCC4.aza1R cells: effects of retinoid-receptor selective ligands.
Mills KJ; Vollberg TM; Nervi C; Grippo JF; Dawson MI; Jetten AM
Cell Growth Differ; 1996 Mar; 7(3):327-37. PubMed ID: 8838863
[TBL] [Abstract][Full Text] [Related]
46. Advances in drug design with RXR modulators.
Vaz B; de Lera ÁR
Expert Opin Drug Discov; 2012 Nov; 7(11):1003-16. PubMed ID: 22954251
[TBL] [Abstract][Full Text] [Related]
47. Rexinoid-induced expression of IGFBP-6 requires RARbeta-dependent permissive cooperation of retinoid receptors and AP-1.
Uray IP; Shen Q; Seo HS; Kim H; Lamph WW; Bissonnette RP; Brown PH
J Biol Chem; 2009 Jan; 284(1):345-353. PubMed ID: 18957410
[TBL] [Abstract][Full Text] [Related]
48. Retinoid X receptor-specific retinoids inhibit the ability of retinoic acid receptor-specific retinoids to increase the level of insulin-like growth factor binding protein-3 in human ectocervical epithelial cells.
Hembree JR; Agarwal C; Beard RL; Chandraratna RA; Eckert R
Cancer Res; 1996 Apr; 56(8):1794-9. PubMed ID: 8620495
[TBL] [Abstract][Full Text] [Related]
49. Regulation of aromatase by nuclear receptors.
Yanase T; Mu YM; Nishi Y; Goto K; Nomura M; Okabe T; Takayanagi R; Nawata H
J Steroid Biochem Mol Biol; 2001 Dec; 79(1-5):187-92. PubMed ID: 11850224
[TBL] [Abstract][Full Text] [Related]
50. Retinoids and rexinoids inhibit hepatitis C virus independently of retinoid receptor signaling.
Murakami Y; Fukasawa M; Kaneko Y; Suzuki T; Wakita T; Fukazawa H
Microbes Infect; 2014 Feb; 16(2):114-22. PubMed ID: 24177211
[TBL] [Abstract][Full Text] [Related]
51. Design and synthesis of potent retinoid X receptor selective ligands that induce apoptosis in leukemia cells.
Boehm MF; Zhang L; Zhi L; McClurg MR; Berger E; Wagoner M; Mais DE; Suto CM; Davies JA; Heyman RA
J Med Chem; 1995 Aug; 38(16):3146-55. PubMed ID: 7636877
[TBL] [Abstract][Full Text] [Related]
52. Synthesis and structure-activity relationships of stilbene retinoid analogs substituted with heteroaromatic carboxylic acids.
Beard RL; Chandraratna RA; Colon DF; Gillett SJ; Henry E; Marler DK; Song T; Denys L; Garst ME; Arefieg T
J Med Chem; 1995 Jul; 38(15):2820-9. PubMed ID: 7636843
[TBL] [Abstract][Full Text] [Related]
53. Effects of rexinoids on thyrotrope function and the hypothalamic-pituitary-thyroid axis.
Sharma V; Hays WR; Wood WM; Pugazhenthi U; St Germain DL; Bianco AC; Krezel W; Chambon P; Haugen BR
Endocrinology; 2006 Mar; 147(3):1438-51. PubMed ID: 16306084
[TBL] [Abstract][Full Text] [Related]
54. Differential effects of rexinoids and thiazolidinediones on metabolic gene expression in diabetic rodents.
Singh Ahuja H; Liu S; Crombie DL; Boehm M; Leibowitz MD; Heyman RA; Depre C; Nagy L; Tontonoz P; Davies PJ
Mol Pharmacol; 2001 Apr; 59(4):765-73. PubMed ID: 11259621
[TBL] [Abstract][Full Text] [Related]
55. Potential therapeutic uses of rexinoids.
Leal AS; Reich LA; Moerland JA; Zhang D; Liby KT
Adv Pharmacol; 2021; 91():141-183. PubMed ID: 34099107
[TBL] [Abstract][Full Text] [Related]
56. Methyl substitution of a rexinoid agonist improves potency and reveals site of lipid toxicity.
Atigadda VR; Xia G; Desphande A; Boerma LJ; Lobo-Ruppert S; Grubbs CJ; Smith CD; Brouillette WJ; Muccio DD
J Med Chem; 2014 Jun; 57(12):5370-80. PubMed ID: 24801499
[TBL] [Abstract][Full Text] [Related]
57. Emerging role of rexinoids in non-small cell lung cancer: focus on bexarotene.
Rigas JR; Dragnev KH
Oncologist; 2005 Jan; 10(1):22-33. PubMed ID: 15632250
[TBL] [Abstract][Full Text] [Related]
58. Pyrazine arotinoids with inverse agonist activities on the retinoid and rexinoid receptors.
García J; Khanwalkar H; Pereira R; Erb C; Voegel JJ; Collette P; Mauvais P; Bourguet W; Gronemeyer H; de Lera AR
Chembiochem; 2009 May; 10(7):1252-9. PubMed ID: 19343742
[TBL] [Abstract][Full Text] [Related]
59. Retinoid X receptor agonists impair arterial mononuclear cell recruitment through peroxisome proliferator-activated receptor-γ activation.
Sanz MJ; Albertos F; Otero E; Juez M; Morcillo EJ; Piqueras L
J Immunol; 2012 Jul; 189(1):411-24. PubMed ID: 22661092
[TBL] [Abstract][Full Text] [Related]
60. Nonclassical retinoids and lung carcinogenesis.
Dragnev KH; Petty WJ; Ma Y; Rigas JR; Dmitrovsky E
Clin Lung Cancer; 2005 Jan; 6(4):237-44. PubMed ID: 15694016
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
